
News|Articles|February 1, 2010
Formulary Digital Edition February 2010
Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis; Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes; and Agents in late-stage development for renal diseases
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Zepbound linked to lower healthcare costs in older adults with obesity
2
FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients
3
Biosimilars provide modest cost savings for cancer patients, study finds
4
FDA approves brepocitinib for rare skin disease
5













